Hudson Bay Capital Management LP Bluebird Bio, Inc. Transaction History

Hudson Bay Capital Management LP

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$0.91 - $1.75 $913,023 - $1.76 Million	-1,003,322 Reduced 45.95%	1,180,115 $1.51 Million
Q4 2023 Feb 14, 2024	BUY	$1.32 - $4.83 $2.45 Million - $8.96 Million	1,855,937 Added 566.7%	2,183,437 $3.01 Million
Q3 2023 Nov 14, 2023	BUY	$3.02 - $4.05 $83,050 - $111,375	27,500 Added 9.17%	327,500 $995,000
Q1 2023 May 15, 2023	BUY	$3.14 - $8.22 $800,700 - $2.1 Million	255,000 Added 566.67%	300,000 $954,000
Q4 2022 Feb 14, 2023	SELL	$5.77 - $8.49 $548,150 - $806,550	-95,000 Reduced 67.86%	45,000 $311,000
Q3 2022 Nov 14, 2022	BUY	$3.75 - $7.39 $525,000 - $1.03 Million	140,000 New	140,000 $886,000
Q4 2020 Feb 12, 2021	SELL	$27.5 - $37.92 $756,250 - $1.04 Million	-27,500 Closed	0 $0
Q3 2020 Nov 12, 2020	SELL	$34.44 - $43.75 $258,299 - $328,125	-7,500 Reduced 21.43%	27,500 $1.48 Million
Q2 2020 Aug 12, 2020	SELL	$27.12 - $45.97 $135,600 - $229,850	-5,000 Reduced 12.5%	35,000 $2.14 Million
Q1 2020 May 14, 2020	BUY	$26.16 - $63.5 $1.05 Million - $2.54 Million	40,000 New	40,000 $1.84 Million
Q3 2019 Nov 13, 2019	SELL	$59.47 - $93.1 $2.68 Million - $4.19 Million	-45,000 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$75.84 - $105.21 $2.28 Million - $3.16 Million	30,000 Added 200.0%	45,000 $5.72 Million
Q1 2019 May 15, 2019	BUY	$64.44 - $104.11 $966,600 - $1.56 Million	15,000 New	15,000 $2.36 Million
Q4 2018 Feb 13, 2019	SELL	$59.1 - $93.26 $910,140 - $1.44 Million	-15,400 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$88.86 - $117.49 $1.37 Million - $1.81 Million	15,400 New	15,400 $2.25 Million

151

63.4M

264K

428K

Ticker BLUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,121,800
Market Cap $27M
Description
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...

Get notified when there are updates to the investment portfolio of Hudson Bay Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Hudson Bay Capital Management LP with notifications on news.